We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA)

This study is currently recruiting participants.
Verified May 2017 by Jeff Healey, Population Health Research Institute
Sponsor:
ClinicalTrials.gov Identifier:
NCT01938248
First Posted: September 10, 2013
Last Update Posted: May 30, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Collaborators:
Bristol-Myers Squibb
Pfizer
Medtronic
Canadian Institutes of Health Research (CIHR)
Hamilton Health Sciences Research Institute
Hamilton Health Sciences Foundation
Information provided by (Responsible Party):
Jeff Healey, Population Health Research Institute
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: April 2021
  Estimated Primary Completion Date: December 2020 (Final data collection date for primary outcome measure)